{"id":"pf-07265028","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT05233436"],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T11:36:15.398288","offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 1 Initiated","description":"Phase 1 trial (PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumor) — Advanced Solid Tumors. Trial terminated early."}],"brandName":"PF-07265028","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"PF-07265028 will be administered orally","explanation":"","oneSentence":"PF-07265028 will be administered orally","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pf-07265028","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Advanced Solid Tumors","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"_fixedFields":["pubmed(1)"],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05233436","phase":"discontinued","title":"PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumor","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":21,"indication":"Advanced Solid Tumors","completionDate":"2023-10","primaryEndpoint":"The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL5435641","pubchemSID":"505953267"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","recentPublications":[{"date":"2024 Dec 26","pmid":"39651809","title":"Discovery of PF-07265028, A Selective Small Molecule Inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) for the Treatment of Cancer.","journal":"Journal of medicinal chemistry"}],"companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","aiSummary":"Pf-07265028, developed by Pfizer Inc., was a discontinued drug. Its mechanism and intended indications are not publicly available due to the discontinuation of its development.","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}